CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.25 USD
-0.10 (-4.26%)
Updated Oct 10, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for CanFite Biopharma Ltd falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -7.63 | -10.17 | -12.62 | -14.44 | -9.59 |
Depreciation/Amortization & Depletion | 0.02 | 0.01 | 0.01 | 0.01 | 0.04 |
Net Change from Assets/Liabilities | -0.94 | -1.30 | 2.49 | 2.00 | 1.19 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.12 | 0.66 | 0.26 | 0.37 | -2.45 |
Net Cash From Operating Activities | -8.44 | -10.80 | -9.86 | -12.06 | -10.80 |
Property & Equipment | 0.00 | -0.01 | -0.01 | -0.03 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.50 | 9.51 | -14.50 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 |
Net Cash from Investing Activities | 0.50 | 9.50 | -14.51 | -0.03 | -0.25 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 9.14 | 0.00 | 20.46 | 17.68 | 10.17 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 9.14 | 0.00 | 20.46 | 17.68 | 10.13 |
Effect of Exchange Rate Changes | 0.10 | -0.11 | 0.03 | -0.02 | 0.00 |
Net Change In Cash & Equivalents | 1.30 | -1.41 | -3.88 | 5.57 | -0.92 |
Cash at Beginning of Period | 2.98 | 4.39 | 8.27 | 2.70 | 3.62 |
Cash at End of Period | 4.28 | 2.98 | 4.39 | 8.27 | 2.70 |
Diluted Net EPS | -3.00 | -3.00 | -9.00 | -12.00 | -33.00 |
Fiscal Year End for CanFite Biopharma Ltd falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -3.96 | NA | -7.63 | NA |
Depreciation/Amortization & Depletion | NA | 0.00 | NA | 0.02 | NA |
Net Change from Assets/Liabilities | NA | -0.45 | NA | -0.94 | NA |
Net Cash from Discontinued Operations | NA | NA | NA | 0.00 | NA |
Other Operating Activities | NA | 0.37 | NA | 0.12 | NA |
Net Cash From Operating Activities | NA | -4.04 | NA | -8.44 | NA |
Property & Equipment | NA | 0.00 | NA | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | NA | NA | NA | 0.00 | NA |
Investments | NA | 4.50 | NA | 0.50 | NA |
Other Investing Activities | NA | NA | NA | 0.00 | NA |
Net Cash from Investing Activities | NA | 4.50 | NA | 0.50 | NA |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | NA | NA | 9.14 | NA |
Issuance (Repayment) of Debt | NA | NA | NA | 0.00 | NA |
Increase (Decrease) Short-Term Debt | NA | NA | NA | 0.00 | NA |
Payment of Dividends & Other Distributions | NA | NA | NA | 0.00 | NA |
Other Financing Activities | NA | NA | NA | 0.00 | NA |
Net Cash from Financing Activities | NA | NA | NA | 9.14 | NA |
Effect of Exchange Rate Changes | NA | -0.02 | NA | 0.10 | NA |
Net Change In Cash & Equivalents | NA | 0.44 | NA | 1.30 | NA |
Cash at Beginning of Period | NA | 4.28 | NA | 2.98 | NA |
Cash at End of Period | NA | 4.72 | NA | 4.28 | NA |
Diluted Net EPS | NA | NA | NA | -0.31 | -0.43 |